U.S. Healthtech Stock News

Himax Technologies (NasdaqGS:HIMX) is back on traders radar after new momentum in its WiseEye AI and FrontLED micro display, as well as progress toward mass producing Co Packaged Optics for AI data centers. See our latest analysis for Himax Technologies. The recent WiseEye and CPO milestones seem to have flipped sentiment, with the share price now at $9.48 and a 26.74% year to date share price return contributing to a 47.10% one year total shareholder return. This suggests momentum is...

If you are wondering whether Molina Healthcare is a quietly compelling value play or a stock to avoid at current levels, you are not alone. This article is going to unpack that in plain English. After falling sharply over the longer term, with the share price down 44.1% year to date and 46.5% over the last year, the stock has recently bounced with a 7.7% gain over the past week and 13.9% over the last 30 days from a last close of $160.52. Much of the recent price action has been driven by...

Raymond James Financial (RJF) just paired a fresh, open ended $2 billion share repurchase authorization with an 8% dividend increase, a combination that usually signals management feels good about cash flows and long term earnings power. See our latest analysis for Raymond James Financial. The news has arrived while Raymond James Financial’s share price has quietly climbed to $166.94, with solid year to date share price returns and a robust five year total shareholder return suggesting...

In early December 2025, A24 announced a limited-edition Marty Supreme Wheaties box featuring Timothée Chalamet, while General Mills introduced Reese's Puffs Dark Chocolate as the brand's first new flavor combo since 1994. Together, these culturally tuned launches show General Mills leaning into entertainment partnerships and product innovation to keep its cereal brands culturally relevant. Next, we’ll examine how the Marty Supreme Wheaties collaboration could influence General Mills’...

Recently, Barclays began covering Envista Holdings, assigning the dental products maker an “Overweight” rating that reflects the bank’s favorable view of the company’s prospects. This new attention from a major financial institution brings Envista more firmly onto institutional investors’ radar, potentially increasing liquidity and broadening its shareholder base. Now we’ll examine how Barclays’ positive initiation of coverage fits with Envista’s existing investment narrative and what it...

If you are wondering whether Surgery Partners is a quietly mispriced opportunity or a value trap in the making, you are not alone. That is exactly what we are going to unpack here. The stock is down 4.9% over the last week and 22.4% year to date, but a 5.0% gain over the past month hints that sentiment may be starting to shift after a long 5 year slide of 42.3%. Recent headlines have focused on Surgery Partners expanding its network of ambulatory surgery centers and deepening relationships...

Earlier this month, Deere & Company expanded its Board from 10 to 11 directors by appointing Cargill Chair and CEO Brian Sikes as an independent director and committee member, while also announcing the upcoming retirement of President, John Deere Financial and CIO Raj Kalathur in January 2026 and affirming a quarterly dividend of US$1.62 per share payable in February 2026. At the same time, President Donald Trump’s public pressure on farm‑equipment pricing and plans to ease environmental...

Earlier this month, Xsolla announced a collaboration with HP to link HP’s Gaming Garage learning platform with Xsolla’s Accelerator, aiming to support over 100,000 aspiring game developers globally through integrated education, incubation, and studio launch pathways. This initiative highlights how HP is using its gaming and education platforms to build long-term engagement with future creators, even as analysts focus on the pressures rising memory costs may place on its core PC business. Now...

If you have been wondering whether Intuitive Surgical is still worth buying at these levels, you are not alone. This breakdown is designed to help you decide with numbers, not hype. The stock has cooled off recently, down about 2.4% over the last week and 3.5% over the last month, but it is still up 6.1% year to date and 98.1% over three years and 117.7% over five years. Those moves sit against a backdrop of steady demand for robotic assisted surgery systems, with hospitals continuing to...

Moog (MOG.A) has quietly rewarded patient shareholders, with the stock up about 21% this year and roughly 19% over the past 3 years, outpacing many industrial and defense peers. See our latest analysis for Moog. That kind of steady 30 day share price return, combined with a powerful multi year total shareholder return, suggests momentum is building as investors reassess Moog's growth prospects and defense exposure at its current 239.2 dollar share price. If Moog's run has you rethinking the...

If you are wondering whether Unity Software is still a bargain after its big rebound, or if the easy money has already been made, this breakdown will help you think through whether the current price really makes sense. The stock has climbed 9.8% over the last week, 13.6% over the past month, and is now up 99.8% year to date. However, the 5 year return of -66.6% is a reminder of how quickly market sentiment around Unity can swing. Recent price action has come alongside ongoing investor...

Earlier this month, Leidos announced a collaboration with CargoSeer to integrate its advanced AI trade-analysis algorithms into the Mezzo™ Enterprise Software Platform, aiming to enhance non-intrusive inspection and border security by giving customs and border agencies instant, unified intelligence on goods crossing international borders. This pairing of Leidos’ inspection software with CargoSeer’s analytics highlights how digital intelligence is becoming central to balancing security...

Wondering if Globant is a beaten down tech name or a quiet value opportunity waiting to be rediscovered? This breakdown will help you decide whether the current price really makes sense. Despite a modest 7.9% rise over the last month, the stock is still down 67.7% year to date and 68.7% over the past year, which indicates that sentiment has been heavily reset even as some investors are starting to edge back in. Recent news has focused on Globant doubling down on digital transformation, AI...

Helios Technologies has announced that Billy Aldridge will become President of its Electronics Segment on January 4, 2026, after serving as Senior Vice President, Managing Director of the segment since March 31, 2025, and building a career across Enovation Controls, FW Murphy, and Brunswick’s MerCruiser/Mercury division. This appointment elevates a leader with deep electronics and OEM experience at a time when Helios is emphasizing customer engagement and growth in its Electronics...

Beam Therapeutics has released updated Phase 1/2 BEACON trial data for its investigational sickle cell therapy risto-cel, showing efficient cell collection, high base-editing levels, and sustained increases in protective hemoglobin F alongside reductions in harmful hemoglobin S in patients with severe vaso-occlusive crises. A key insight is that risto-cel’s manufacturing process appears both efficient and predictable, with most patients needing only a single stem cell collection cycle, which...

If you are wondering whether EchoStar is still a smart buy after its huge run up, or if you have already missed the best part of the move, this breakdown will help you think through whether the current price really makes sense. The stock has surged, jumping 39.6% over the last week, 45.9% in the past month, and an eye-catching 357.1% year to date, which has dramatically changed how the market is pricing its future. These gains have been driven by a wave of attention around EchoStar's role in...

If you have been wondering whether Centrus Energy is still worth buying after its massive run up, you are not alone. This stock has quickly moved from niche nuclear play to front row on many investors watchlists. Even after a recent pullback of 1.3% over the last week and 8.8% over the last month, the share price is still up an eye catching 257.3% year to date and 252.3% over the past year, with longer term holders sitting on gains above 1,000% over five years. That turbocharged performance...

Customers Bancorp (CUBI) is back on investors’ radar after fresh Wall Street coverage highlighted its expanding commercial banking teams and its growing cubiX real time payments platform, a combination that is reshaping its deposit base and funding costs. See our latest analysis for Customers Bancorp. The latest coverage comes as the share price has climbed to $71.65 and logged a robust year to date share price return of just over 51%, while the five year total shareholder return above 300%...

Zoetis Inc. recently announced that Health Canada has approved Portela (relfovetmab injection), a monoclonal antibody designed to provide three months of osteoarthritis pain relief for cats with a single dose, following earlier approval in the European Union. The approval adds a longer-acting companion to Solensia in Zoetis’ feline osteoarthritis portfolio, underscoring how product innovation and geographic expansion could shape its future role in chronic pet pain management. We’ll now...

BWX Technologies (BWXT) just stacked two meaningful wins: a long term Owner's Engineer role on Bulgaria's Kozloduy nuclear expansion and delivery of TRISO fuel for the U.S. Project Pele microreactor, and investors are paying attention. See our latest analysis for BWX Technologies. These wins come after a powerful run, with BWX Technologies’ share price delivering a year to date return of 61.15 percent and a three year total shareholder return of 210.11 percent, suggesting momentum is still...

If you are wondering whether Amphenol is still a smart buy after its huge run, or if you are late to the party, this breakdown will help you assess whether the current price makes sense. The stock has paused recently, remaining flat over the last week and down about 3.6% over the past month. That follows a climb of roughly 101% year to date and 90.1% over the last year. These gains have been supported by steady demand for Amphenol's connectivity and sensor solutions across data centers,...

If you are wondering whether NetApp at around $119 a share is a hidden value play or a stock that has already run its course, you are not alone. This breakdown is designed to unpack exactly that question. The stock has quietly climbed 2.9% over the last week and 8.1% over the last month, yet it is only up 3.0% year to date and is actually down 1.4% over the past year, even after more than doubling over 3 and 5 years. Those mixed returns come as NetApp keeps sharpening its focus on cloud data...

In the past quarter, Zimmer Biomet Holdings reported mixed third-quarter results, with organic sales growth and an earnings beat, but overall revenue came in below consensus expectations, unsettling some investors. This contrast between stronger underlying demand indicators and softer headline revenue highlights how closely the market is watching Zimmer Biomet’s execution on growth. We’ll now explore how the mixed revenue performance, despite organic sales growth, could influence Zimmer...

Kratos Defense & Security Solutions (KTOS) just opened a new 10,000 square foot PT6A and PT6T engine overhaul facility in Vancouver, a strategic expansion aimed at tightening its North American service network and improving operational efficiency. See our latest analysis for Kratos Defense & Security Solutions. The new Vancouver site adds to a year where momentum has clearly been building, with a roughly 191 percent year to date share price return and a remarkable 707 percent three year total...